While SGLT2 inhibitors have become widely used in adults, until 2019 with the advent of glucagon-like peptide-1 (GLP-1) receptor agonists such as liraglutide, the only approved treatments for pediatric patients/children with type 2 diabetes mellitus (T2DM) were insulin and metformin. The gene discussed is INS; the disease is diabetes mellitus.